Valuation : Protalix BioTherapeutics, Inc.

Market Cap 215M 185M 174M 159M 298M 20.31B 298M 2.06B 799M 10.42B 808M 790M 33.57B P/E 2026 *
14.1x
P/E 2027 * 48.5x
Enterprise Value 215M 185M 174M 159M 298M 20.31B 298M 2.06B 799M 10.42B 808M 790M 33.57B EV / Sales 2026 *
2.7x
EV / Sales 2027 * 3.15x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day+1.91%
1 week+5.12%
Current month+3.89%
1 month+12.66%
3 months+32.84%
6 months-5.65%
Current year+48.33%
1 week 2.52
Extreme 2.525
2.68
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.53
Extreme 1.53
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Free

Chairman

25,500 0.0316%
03/09/26 Free

Chief Executive Officer

480,000 0.5957%
03/09/26 Free

Director

25,500 0.0316%
Change 5-day change 1-year change 3-year change Capi.($)
+1.91%+5.12%+67.92%+34.85% 215M
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.70%+1.50%+32.26%+49.50% 367.86B
Weighted average by Cap. -1.10%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 79.8M 68.66M 64.6M 59.02M 110M 7.53B 111M 763M 296M 3.87B 300M 293M 12.45B 68.19M 58.68M 55.21M 50.44M 94.35M 6.44B 94.61M 652M 253M 3.3B 256M 250M 10.64B
Net income 15.38M 13.23M 12.45M 11.37M 21.27M 1.45B 21.33M 147M 57.08M 745M 57.73M 56.48M 2.4B 4.46M 3.84M 3.61M 3.3M 6.17M 421M 6.19M 42.7M 16.57M 216M 16.76M 16.39M 696M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
04/09/26 $2.670 +1.91% 863,718
03/09/26 $2.620 +1.16% 942,012
02/09/26 $2.590 0.00% 454,863
01/09/26 $2.590 +0.78% 598,262
31/08/26 $2.570 +1.18% 748,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.670USD
Average target price
11.00USD
Spread / Average Target
+311.99%

Quarterly revenue - Rate of surprise